SCHEMBL78675

SCHEMBL78675

O=Cc1cc(C(F)(F)F)ccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
HPGD P15428 3/20 0.59
KDM4E B2RXH2 2/20 0.59
HSD17B10 Q99714 2/20 0.59
USP2 O75604 1/20 0.51
CYP2C19 P33261 1/20 0.51
CES2 O00748 2/20 0.49
GRIK1 P39086 1/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
ALOX12 P18054 1/20 0.44
KMT2A Q03164 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
SORT1 Q99523 5/20 0.43
ACLY P53396 1/20 0.43
TAS2R14 Q9NYV8 2/20 0.42
LIPC P11150 1/20 0.42
LIPG Q9Y5X9 1/20 0.42
SRD5A2 P31213 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78139 0.86 ALDH1A1 (0.54) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL22265173 0.84 ALDH1A1 (0.57) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL10040180 0.82 KDM4E (0.41) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL16566877 0.80 CFTR (0.63) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL460066 0.79 KDM4E (0.69) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL424263 0.77 CES2 (0.78) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL6928663 0.77 KEAP1 (0.52) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL28592330 0.77 PDPK1 (0.46) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL29604269 0.77 PDPK1 (0.46) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL6853258 0.77 POLB (0.42) ALDH1A1HPGDKDM4EHSD17B10CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828253-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME Abide Therapeutics, Inc. (US) 2015-01-28 EP disclosed
WO-2013142307-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS (US) 2013-09-26 WO disclosed
US-8129381-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8071618-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-06 US disclosed
US-20100137359-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-03 US disclosed
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-12 US disclosed
US-7612091-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
EP-1581501-A1 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2005-10-05 EP disclosed
EP-1539701-A1 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-06-15 EP disclosed
US-20040192612-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-09-30 US disclosed
WO-2004058718-A1 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-07-15 WO disclosed
US-20040072850-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-04-15 US disclosed
WO-2004002961-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137359-A1 CASPASE INHIBITORS AND USES THEREOF CASP3, CASP1, CASP5 ALDH1A1 2935/4885HPGD 3302/4885KDM4E 2622/4885
US-20040072850-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP2 ALDH1A1 862/4885HPGD 917/4885KDM4E 2431/4885
US-20040192612-A1 Caspase inhibitors and uses thereof CASP1, CASP3, CASP5 ALDH1A1 2450/4885HPGD 3159/4885KDM4E 1210/4885
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 ALDH1A1 1366/4885HPGD 764/4885KDM4E 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.